Blincyto is a type of immunotherapy called a bispecific monoclonal antibody. This means that it binds to two different molecules at the same time – a protein called CD19 which exists on the surface of B-cell leukemia or lymphoma cells and a protein called CD3 which is expressed on T cells (a specific type of immune system cell). Blincyto may also be called a targeted treatment.